Stacie B. Dusetzina

Jun 6, 2024 | healthaffairs.org | Betsy Q. Cliff |Stacie B. Dusetzina

Affordable health care is increasingly out of reach for people who get insurance through their employers, including most people younger than age 65. While low-income employees are among the most vulnerable, the majority of Americans, and most of their employers as well, now say health costs, especially out-of-pocket costs for medical care, are the country’s most urgent health issue.

May 24, 2024 | healthaffairs.org | Stacie B. Dusetzina

Over the past decade, there have been major advances in treatments for diseases including curative therapies for hepatitis C and cell and gene therapies for rare and complex illnesses (for example, lymphoma, sickle cell, beta thalassemia). These drugs receive significant attention from clinicians and patients who have long waited for more effective treatments but also draw attention from the public, the media, and policy makers because of their high prices and budgetary implications for payers.

Nov 20, 2023 | jamanetwork.com | Stacie B. Dusetzina |Francis J. Crosson |Aaron S. Kesselheim

Medicare Part D Payments for Generic Imatinib From 2017 to 2023 Imatinib is among the most effective cancer drugs ever developed.1 At US Food and Drug Administration (FDA) approval in 2003, imatinib was the most expensive medication available. This high launch price and price increases have contributed to low patient adherence to therapy,2 making entry of generic versions eagerly anticipated.

Sep 5, 2023 | jamanetwork.com | Utibe R. Essien |Stacie B. Dusetzina

As the COVID-19 pandemic raged on in mid- to late 2020, there was little to bring hope, as social distancing continued, classrooms and offices remained shuttered, and individuals and families struggled to conduct their lives largely from home. Yet through all the challenges, loss, and despair, the one sign of optimism came from the expectation of a COVID-19 vaccine.

Jul 18, 2023 | jamanetwork.com | Michael Kyle |Stacie B. Dusetzina |Nancy L. Keating

Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020 Utilization management—such as prior authorization—is prevalent, and evidence from medical services indicates it disproportionately affects oncology treatments.1 Orally administered cancer drugs are increasing in number and cost.2 These products have mandatory coverage in Medicare Part D as a protected class; less is known about utilization management.